- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Iovance Biotherapeutics Inc (2LB)Iovance Biotherapeutics Inc stock price live, this page displays NASDAQ IOVA stock exchange data. View the IOVA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Iovance Biotherapeutics Inc real time stock price chart below.
What Is the Iovance Biotherapeutics Inc Stock Price Today?
The Iovance Biotherapeutics Inc stock price today is 8.202.
What Is the Stock Symbol for Iovance Biotherapeutics Inc?
The stock symbol for Iovance Biotherapeutics Inc is "IOVA."
What Stock Exchange Does Iovance Biotherapeutics Inc Trade On?
Iovance Biotherapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Iovance Biotherapeutics Inc a Good Stock to Buy?
Determining whether Iovance Biotherapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IOVA quote. (ISIN: US4622601007)
What Is the Iovance Biotherapeutics Inc Stock Price Today?
The Iovance Biotherapeutics Inc stock price today is 8.202.
What Is the Stock Symbol for Iovance Biotherapeutics Inc?
The stock symbol for Iovance Biotherapeutics Inc is "IOVA."
What Stock Exchange Does Iovance Biotherapeutics Inc Trade On?
Iovance Biotherapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Iovance Biotherapeutics Inc a Good Stock to Buy?
Determining whether Iovance Biotherapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IOVA quote. (ISIN: US4622601007)
8.202
+0.090(+1.11%)
Closed
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.128
8.202
52 wk Range
5.834
16.850
2LB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.1288.202
52 wk Range
5.83416.850
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
2LB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Price Target
23.770
Upside
+198.618%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Iovance Biotherapeutics Inc Company Profile
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Compare 2LB to Peers and Sector
Metrics to compare | 2LB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2LBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.4x | −2.4x | −0.6x | |
PEG Ratio | −0.23 | 0.03 | 0.00 | |
Price/Book | 3.4x | 2.3x | 2.6x | |
Price / LTM Sales | 28.8x | 12.7x | 3.2x | |
Upside (Analyst Target) | - | 337.7% | 40.6% | |
Fair Value Upside | Unlock | 22.3% | 7.1% | Unlock |
People Also Watch
FAQ
What Is the Iovance Biotherapeutics (2LB) Stock Price Today?
The Iovance Biotherapeutics stock price today is 8.202
What Stock Exchange Does Iovance Biotherapeutics Trade On?
Iovance Biotherapeutics is listed and trades on the Frankfurt stock exchange.
What Is the Stock Symbol for Iovance Biotherapeutics?
The stock symbol for Iovance Biotherapeutics is "2LB."
What Is the Iovance Biotherapeutics Market Cap?
As of today, Iovance Biotherapeutics market cap is 2.33B.
What is Iovance Biotherapeutics Earnings Per Share?
The Iovance Biotherapeutics EPS is -1.48.
From a Technical Analysis Perspective, Is 2LB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.